Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Deep and rapid responses with a dexamethasone-sparing combination of daratumumab and lenalidomide in
    elderly patients with multiple myeloma

2. The TRIANGLE trial supports ibrutinib as part of the first-line treatment for transplant-eligible mantle cell
    lymphoma

3. Significant benefit from the addition of isatuximab to carfilzomib-dexamethasone irrespective of the time to
    relapse on prior therapy in patients with relapse/refractory multiple myeloma

4. Liso-cel as a preferred second line treatment for patients with primary refractory or early relapsed LBCL

5. Blinatumomab with consolidation chemotherapy prolongs the overall survival of patients with MRD-negative
    B-Cell ALL